依达拉奉治疗急性脑梗死的临床研究  

Investigation of the therapeutic effects of edaravone on acute cerebral infarction

作　　者：赵淑琴[1] 张海欣[2] 顾俊琴[3] 

机构地区：[1]河北大学附属医院内科,保定071000 [2]河北省保定市第二医院神经内科,保定071051 [3](河北省保定市儿童医院内五科,保定071051

出　　处：《药学与临床研究》2007年第1期57-60,共4页Pharmaceutical and Clinical Research

摘　　要：目的:研究依达拉奉治疗脑梗死时对丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)的影响及疗效。方法:入选200例患者,随机分为依达拉奉组105例、对照组95例,在治疗前、治疗后第4、7、11、15天采静脉血测定MDA、SOD、GSH-Px浓度,并进行治疗前、后ESS评定。结果:与治疗前相比,治疗后第11、15天按欧洲神经功能缺损评分量表(ESS)衡量明显增高,(P<0.01)。治疗后第4、7、11、15天,MDA较治疗前降低,(P<0.01);SOD、GSH-Px较治疗前升高,(P<0.01)。在第15天时,三者处于稳定状态。结论:依达拉奉降低MDA,升高SOD、GSH-Px,清除自由基,保护脑细胞,有助于降低脑梗死致残率。Objective： Edaravone, a free radical scavenger approved for treatment of acute cerebral infarction （ACI） ; the purpose of the present study was to evaluate its efficacy including investigating sequential changes in serum concentrations of malondialdehyde （MDA）, superoxide dismutase （SOD）, glutathione peroxides （GSH-Px） in patients with ACI. Method： Within an open trial design, 200 subjects with ACI received either 60-30mg （ 105 subjects） of edaravone via intravenous drip or routine treatment （95 subjects）. 10 days of administration was followed by a two-week observation period and the efficacy was evaluated by European stroke scales （ESS）. Results： ESS score of the llth and 15th day after treatment was markedly raised than that before （p 〈 0.01）, the serum MDA level was decreased on the 4th 7th 11th 15th day after treatment （p 〈0.01）, and the concentration of SOD ,GSH-Px were raised respectively （p 〈0.01 ）. Conclusion： Data from the present study suggest that edaravone is safe and may reduce the disablement rate of ACI by reducing MDA level and increasing the concentration of SOD and GSH-Px.

关 键 词：依达拉奉 丙二醛 超氧化物歧化酶 谷胱甘肽过氧化物酶 脑梗死 疗效 

分 类 号：R969.4[医药卫生—药理学]